CAS 263707-16-0
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
7 produits concernés.
3-Isoxazolepropanenitrile, α-[2-(3-chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-β-oxo-
CAS :Formule :C16H15ClN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :330.7689ESI-09
CAS :<p>ESI-09 is a new-typel noncyclic nucleotide EPAC antagonist.The IC50 values of ESI-09 for EPAC1 and EPAC2 is 3.2 and 1.4 μM, respectively.</p>Formule :C16H15ClN4O2Degré de pureté :97.24% - 99.57%Couleur et forme :SolidMasse moléculaire :330.77ESI 09
CAS :Produit contrôlé<p>Applications ESI 09 acts as an EPAC inhibitor, preventing EPAC-mediated insulin release form β-pancreatic cells. Selective control for EPAC over PKA and decreases migration and invasion of AsPc-1 and PANC-1 pancreatic cancer cells.<br>References Tao, X. et al.: J. Virol., 88, 3902 (2014); Almahariq, M. et al.: Mol. Pharm., 83, 122 (2013);<br></p>Formule :C16H15ClN4O2Couleur et forme :NeatMasse moléculaire :330.769ESI-09
CAS :Formule :C16H15ClN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :330.77ESI-09
CAS :<p>ESI-09 is a novel drug candidate that has been shown to have synergistic effects with chemotherapeutic agents in the treatment of cancer. It is a potential drug target for cancer, and its anticancer activity may be due to its ability to reduce oxidative stress by activating antioxidant enzymes. ESI-09 has antioxidative properties and decreases the mitochondrial membrane potential, which leads to increased ATP levels. ESI-09 also has the ability to cause cell death by inhibiting aerobic glycolysis, which may be due to its inhibitory effects on the polymerase chain reaction (PCR).</p>Formule :C16H15ClN4O2Degré de pureté :Min. 95%Masse moléculaire :330.77 g/mol
![3-Isoxazolepropanenitrile, α-[2-(3-chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-β-oxo-](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA002SX8.jpg&w=3840&q=75)
